Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q2 2026 · 10-Q
Revenue$12.59B$12.59B+13.0% vs Q2 2025 Net Income$928.00M$928.00M−47.8% vs Q2 2025 EPS Diluted$0.53$0.53−47.5% vs Q2 2025 Operating Income$1,693,000,000−17.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,991,000,000+28.9% Margins · derivedOperating margin13.4%−5.0 pt vs Q2 2025
Net margin7.4%−8.6 pt vs Q2 2025
ended Jun 30, 2026 · filed Jul 28, 2026 · 28 d after period end